8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
Dexcom reports 11% revenue growth and authorizes $1 billion share buyback
Filed with the SEC on · Summarized by InvestorsBot
Dexcom reported third-quarter 2026 revenue of $1.344 billion, up 11% year over year, with GAAP diluted EPS of $0.72 and GAAP operating margin of 24.3%. The company raised its 2026 revenue guidance to $5.20-$5.25 billion and authorized up to $1.0 billion in common-stock repurchases through December 31, 2027, although it is not required to buy any shares and may change or end the program at any time.